A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)